Star Sports Medicine Co (HKSE:01609) Stock Based Compensation: HK$0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01609 Star Sports Medicine Co Ltd HKSE:01609
20 GF Score
Price HK$106.70
! 1 Warning Sign
View Full Analysis

What is Star Sports Medicine Co Stock Based Compensation?

Star Sports Medicine Co HKSE:01609 -5.32% 20 Stock Based Compensation is HK$0.0 Mil as of Dec. 2025. GuruFocus rates HKSE:01609 with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Star Sports Medicine Co's Stock Based Compensation for the three months ended in Dec. 2025 was HK$0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.0 Mil.

Star Sports Medicine Co Stock Based Compensation Related Terms

Star Sports Medicine Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Star Sports Medicine Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Star Sports Medicine Co Stock Based Compensation Chart

Star Sports Medicine Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
0.00 0.99 1.16 1.33

Star Sports Medicine Co Quarterly Data
Dec22 Dec23 Dec24 Sep25 Dec25 Jun26
Stock Based Compensation Get a 7-Day Free Trial 0.00 0.29 0.00 0.00 0.00
HKSE:01609
20GF Score
Star Sports Medicine Co Ltd HKSE:01609
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Star Sports Medicine Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

What does a Stock Based Compensation of HK$0.0 Mil mean?
Star Sports Medicine Co (HKSE:01609) has a Stock Based Compensation of HK$0.0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Star Sports Medicine Co and its competitors.
Is Star Sports Medicine Co's Stock Based Compensation too high?
Star Sports Medicine Co's current Stock Based Compensation is HK$0.0 Mil. Overall, Star Sports Medicine Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Star Sports Medicine Co's Stock Based Compensation compare to ABT and SYK?
Star Sports Medicine Co's Stock Based Compensation of HK$0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Star Sports Medicine Co and its competitors. Star Sports Medicine Co's current Stock Based Compensation is HK$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Sports Medicine Co stock overvalued right now?
Star Sports Medicine Co (HKSE:01609) has a current Stock Based Compensation of HK$0.0 Mil. The current Stock Based Compensation is HK$0.0 Mil. Star Sports Medicine Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Star Sports Medicine Co (HKSE:01609), the current Stock Based Compensation is HK$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Star Sports Medicine Co Business Description

Address No. 25, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Building 1, A018, B018, Beijing, CHN
Star Sports Medicine Co Ltd is a China-based medical device company specializing in clinical sports medicine solutions. It is principally engaged in the research and development and sales of medical devices and equipment in the field of sports medicine. The product line covers medical implants, surgical equipment and associated medical consumables. The company has only one reportable operating segment, which is the sale of sports medicine products. It derives revenue from the sales of (i) medical implants and (ii) surgical equipment and associated medical consumables, with the majority of revenue generated from the sales of Medical implants. Geographically, the maximum revenue is derived from the Chinese mainland.
20GF Score

Get the complete analysis for HKSE:01609

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$106.70
Price